Fulminant hepatic failure during pregnancy.

Zahra Nazish¹, Muhammad Inayatullah², Fatima Tu Zahra³

ABSTRACT… Objective: To observe clinical characteristics, etiology and maternal outcome in fulminant hepatic failure during pregnancy. Study Design: Observational Prospective Study. Setting: Department of Medicine, Nishtar Hospital Multan. Period: January 2013 to December 2017. Material & Methods: Twenty nine consecutive patients with fulminant hepatic failure during pregnancy were included in the study. Results: Mean age of patients was 27.06±6.92 years. 65.51% patients were from urban areas. Mean duration of gestation was 24.80±6.03 weeks. Jaundice and altered consciousness were observed in 100% cases, pallor in 79.31%, hepatomegaly in 20.68%, flapping tremors in 10.34%, ascites in 10.34% and splenomegaly in 6.89% cases. Complications observed were cerebral edema in 44.82%, renal failure in 24.13%, bleeding in 20.68% and hypoglycemia in 3.44%. Most common cause was acute hepatitis E (75.86%) followed by hepatitis B (13.79%) and hepatitis A (3.44%). No cause was found in 6.89% cases. Overall maternal mortality was 37.93% and fetal mortality was 72.41%. In 17.24% cases pregnancy was terminated therapeutically, 44.82% cases had spontaneous expulsion and in 37.93% cases pregnancy continued. Maternal mortality was highest (45.45%) in patients who remained pregnant as compared to 20% when pregnancy was terminated therapeutically. Conclusion: Jaundice and altered conscious level is the most common clinical presentation. Hepatitis E is the most common cause of FHF in pregnancy. Maternal mortality in FHF during pregnancy is very high.

Key words: Fulminant Hepatic Failure, Maternal Outcome, Pregnancy.

INTRODUCTION

Fulminant hepatic failure (FHF) in pregnancy, although uncommon, is a serious condition associated with high maternal and fetal mortality.

There are many causes of FHF but viral hepatitis is most common in our country. Viral hepatitis is caused by six types of virus: hepatitis A, B, C, D, E and G. Hepatitis E in pregnancy is associated with severe liver dysfunction and progression to acute liver failure.¹ FHF presents with altered mental status, derangement of liver function tests and coagulopathy. FHF has 40% mortality and liver transplantation is the only treatment option.² Facility of liver transplantation is not available in our set up. Management is supportive and we wait for liver to regenerate.

In pregnant women there is excessive metabolic burden on the liver which makes it difficult to recover. Because of the interaction between pregnancy and hepatitis, there is severe immunologic response and a large number of liver cells will undergo necrosis rapidly. Therefore acute hepatitis can aggravate very quickly and complications are more likely to develop.³,⁴ Maternal mortality is reported to be high in many parts of the world in FHF.⁵

Rationale of this study was to enhance our knowledge about the clinical characteristics, etiology, and maternal outcome in FHF during pregnancy so as to identify appropriate measures to reduce morbidity and mortality.

OBJECTIVE

To observe clinical characteristics, etiology and maternal outcome in fulminant hepatic failure during pregnancy.
Fulminant hepatic failure during pregnancy.

MATERIAL & METHODS
This study was conducted in the department of Medicine Nishtar Hospital Multan from January 2013 to December 2017 after permission from Head of department. Consecutive 29 patients who presented with fulminant hepatic failure during pregnancy were included in the study. Patients with underlying chronic liver disease were excluded. Patients were evaluated on the basis of history, examination and investigations including liver function tests, serum albumin, prothrombin time, renal parameters, viral serology (IgM anti HAV, HBsAg, IgM anti HBC, anti HCV, IgM anti HEV), serum uric acid and abdominal ultrasound. CT scan head was done in patients with signs of raised intracranial pressure. Patients were classified into three groups based on outcome of pregnancy (therapeutic termination of pregnancy, spontaneous expulsion of fetus, pregnancy continued).

Data was analysed using Statistical Package for Social Sciences (SPSS) version 20. Descriptive analysis was applied to calculate frequency and percentage for qualitative variables. Mean and standard deviation was calculated for quantitative variables.

RESULTS
Mean age of our patients was 27.06±6.9 (18 – 45) years. Nineteen (65.51%) patients were from urban areas and 10 (34.48%) from rural areas. Twenty six (89.65%) patients were housewives. Mean duration of gestation at the time of presentation was 24.80±6.03 (8-32) weeks.

Twenty nine (100%) patients presented with altered consciousness, 26(89.65%) with yellowness of eyes, 10(34.48%) with fever, 06(20.68%) with vomiting, 03(10.34%) with pain in right hypochondrium.

The most common signs were jaundice observed in 29(100%) cases and pallor observed in 23(79.31%) cases. Mean duration of jaundice at the time of presentation was 9.2±16.6 (1-90 days) days and encephalopathy was 1.92±1.1 (1-5) days. Other signs observed were hepatomegaly 6(20.68), flapping tremors 3(10.34%), ascites 3(10.34%) and splenomegaly 2 (6.89%).

Mean serum bilirubin level was 14.3±9.0 (2.7-44.3)mg/dl, ALT was 1070±1249.95 (32-5972) U/L, PT was 38.6±30.65 (15-120) secs and serum albumin 2.8±1.06 (1.7-5.6) gm/dl. Mean serum creatinine was 1.2±1.0 (0.5-4.16) mg/dl and mean serum uric acid was 4.9±2.8 mg/dl (2-11.6) mg/dl. IgM anti HAV was present in 1(3.44%), HBsAg + IgM Anti HBC in 4(13.79%) and IgM anti HEV in 22(75.86%) and no cause was found in 2 (6.89%). Thirteen patients (44.82%) had signs of raised intracranial pressure, 6% (20.68) had bleeding and 7% (24.13) had renal failure. (Table I and II shows demographic, clinical and biochemical parameters of all patients).

Fourteen (48.27%) patients were stable and discharged, 11% (37.93) expired and 4 % (13.79) left against medical advice. Only 7 (24.13%) babies were born alive. (Table-III)

For comparison we divided our patients into three groups based on outcome of pregnancy: In 5 (17.24%) cases pregnancy was terminated therapeutically after taking high risk consent from patients near relative. Thirteen (44.82%) patients had a spontaneous expulsion of fetus and in 11 (37.93%) patients pregnancy continued.

Demographic, clinical and biochemical features and maternal and fetal outcomes were compared in three groups (Table-IV and V).

DISCUSSION
Fulminant hepatic failure includes a spectrum of clinical features characterized by acute liver injury, severe hepatocellular dysfunction and hepatic encephalopathy. Hepatitis E is the most common cause of fulminant hepatic failure in pregnancy. Pregnant women in developing countries are at an increased risk of acute hepatitis E and its serious complications. Maternal mortality due to fulminant hepatitis E is higher as compared to other causes of FHF. Both maternal and fetal complications can occur including abortion, premature labour, postpartum haemorrhage, maternal and fetal or
neonatal death.\textsuperscript{7} Management is supportive and termination of pregnancy is not done routinely.\textsuperscript{8}

| Age (years) | Range (mean±SD)/ N (%) |
|-------------|------------------------|
| 18-45       | (27.06±6.92)           |

| Residence       | N (%)         |
|-----------------|---------------|
| Urban           | 19 (65.51)    |
| Rural           | 10 (34.48)    |

| Occupation     | N (%)         |
|----------------|---------------|
| Housewife      | 26 (89.65)    |
| Working        | 03 (10.34)    |

| Duration of gestation (weeks) | Range (mean±SD)/ N (%) |
|------------------------------|------------------------|
| 8-32                         | (24.80±6.03)           |

| Duration of jaundice (days)  | Range (mean±SD)/ N (%) |
|------------------------------|------------------------|
| 01-90                        | (9.2±16.6)             |

| Duration of CNS symptoms (days) | Range (mean±SD)/ N (%) |
|---------------------------------|------------------------|
| 01-05                           | (1.92±1.1)             |

| Yellowness of eyes and skin    | N (%)          |
|--------------------------------|----------------|
| 26                             | (89.65)        |

| Fever                         | N (%)          |
|-------------------------------|----------------|
| 10                            | (34.48)        |

| Vomiting                     | N (%)          |
|-------------------------------|----------------|
| 06                            | (20.68)        |

| Pain right hypochondrium     | N (%)          |
|-------------------------------|----------------|
| 03                            | (10.34)        |

| Altered/loss of consciousness| N (%)          |
|-------------------------------|----------------|
| 29                            | (100)          |

| Fits                          | N (%)          |
|-------------------------------|----------------|
| 09                            | (31.03)        |

| Jaundice                     | N (%)          |
|-------------------------------|----------------|
| 29                            | (100)          |

| Pallor                       | N (%)          |
|-------------------------------|----------------|
| 23                            | (79.31)        |

| Flapping tremors             | N (%)          |
|-------------------------------|----------------|
| 03                            | (10.34)        |

| Hepatomegaly                 | N (%)          |
|-------------------------------|----------------|
| 06                            | (20.68)        |

| Splenomegaly                 | N (%)          |
|-------------------------------|----------------|
| 02                            | (6.89)         |

| Ascites                      | N (%)          |
|-------------------------------|----------------|
| 03                            | (10.34)        |

| GCS                           | N (%)          |
|-------------------------------|----------------|
| 03-15                         | (7±3.2)        |

| cerebro edema/Raised ICP     | N (%)          |
|-------------------------------|----------------|
| 13                            | (44.82)        |

| Renal failure                | N (%)          |
|-------------------------------|----------------|
| 07                            | (24.13)        |

| Bleeding                     | N (%)          |
|-------------------------------|----------------|
| 06                            | (20.68)        |

| Hypoglycaemia                | N (%)          |
|-------------------------------|----------------|
| 01                            | (3.44)         |

Table-I. Clinical characteristics of FHF in pregnancy. (N=29).

| Range (mean±SD)/ N (%) | Range (mean±SD)/ N (%) |
|------------------------|------------------------|
| Bilirubin (mg/dl)      | 2.7-44.3 (14.3±9.0)    |
| ALT U/L                | 32-5972 (1070±1249.95) |
| AST U/L                | 42-3775 (597.2±887.9)  |
| ALP U/L                | 134-679 (287.95±131.4) |
| PT sec                 | 15-120 (38.6±30.65)    |
| S/Albumin gm/dl        | 1.7-5.6 (2.8±1.06)     |

| Viral serology           | Anti-HAV Ab         |
|--------------------------|---------------------|
|                          | 01 (3.44)           |

| HBsAg + IgM anti HBC Ab  | Anti HEV Ab         |
|--------------------------|---------------------|
| 04 (13.79)               | 22 (75.86)          |

| None                      | Serum uric acid (mg/dl) |
|----------------------------|-------------------------|
|                            | 02-11.6 (4.9±2.8)       |

| Serum creatinine (mg/dl)  | N (%)          |
|----------------------------|----------------|
| 0.5-4.16 (1.2±1.0)        |

Table-II. Lab investigations of FHF in pregnancy. (N=29)

In our study, the mean age of patients was 27.06±6.92 years. Similarly mean age of patients observed by Brohi et al in Isra University Hospital Hyderabad was 29.04±8.404 years and by Khuro et al was 28.74 ± 5.76 years.\textsuperscript{9,10} Desai observed a mean age of 24.8±0.6 years.\textsuperscript{7} So patients in most of the studies were in third decade of life.

Our study demonstrated that 34.5% patient’s belonged to rural areas as compared to 73.1% patients from rural areas in Brohi’s study.\textsuperscript{9} This shows that in our country pregnant women in rural areas have limited access to a tertiary care hospital for their medical problems.

In our study mean duration of gestation at the time of presentation was 6.2±1.52 months. Brohi observed that 80.7% patients presented in third trimester.\textsuperscript{9}

We observed that mean duration of jaundice at the time of presentation was 9.21±16.66 days while Sahai observed a mean duration of 4.57±2.932 days.\textsuperscript{11} It also shows that patients present late to tertiary care hospitals after onset of jaundice.

Mean duration of encephalopathy at presentation was 1.92±1.1 days in our study while it was 20 hours as observed by Patra et al.\textsuperscript{12} This again shows late referral of our serious patients to tertiary care hospital.

Jaundice was present in 100% of our cases. Li also observed jaundice in 100% cases\textsuperscript{3} while Sahai found it in only 58% patients.\textsuperscript{11}

We found hepatitis A in 3.4% cases while Sahai found it in 13.5% cases.\textsuperscript{11} This shows that hepatitis A is uncommon in adults as 96% of our population is exposed to it before the age of 5, so adults are immune.\textsuperscript{11}

Hepatitis B was seen in 13.79% patients. Brohi observed hepatitis B in 17.3% cases and Sahai in 7.4%.\textsuperscript{9,11}

We found HEV in 75.9% cases. Similarly Sahai observed hepatitis E in 77.9% cases.\textsuperscript{11} Brohi and Shuaib in Pakistan observed hepatitis E in 53.
Fulminant hepatic failure during pregnancy

Conversely, Khuroo found that 95.7% patients of FHF had HEV infection. As hepatitis E spreads by feco-oral route so this indicates lack of good sanitation and clean drinking water in these countries. Beniwal also reported HEV as the most common etiology of FHF in pregnancy. We did not observe any case of hepatitis C similar to Beniwal and Khuroo et al while Sahai observed acute hepatitis C in 1.5% cases. On the other hand, Brohi observed it in 13.5% cases. Hepatitis C was previously considered a rare cause of fulminant hepatic failure but now observed as an important cause in many studies.

We did not find any case of acute fatty liver of pregnancy which is also an important cause of FHF in pregnancy. Sahai reported acute fatty liver of pregnancy in 3.57% cases. We could not find...
Fulminant hepatic failure during pregnancy

any etiology in 2% cases. The underlying cause might be AFLP which in the early phase is similar to viral hepatitis.

We found mean bilirubin of 14.3±9.0 mg/dl and Brohi observed mean bilirubin of 18.144±6.72 mg/dl indicating significant liver dysfunction. While Sahai found that mean Bilirubin was 8.52±6.11 mg/dl.

Mean PT (Prothrombin time) of our patients was 38.6±30.65 seconds comparable with other studies (46.58 and 26.19±23.02 seconds in Brohi’s and Sahai’s patients respectively). Mean serum albumin of our patients was 2.8±1.06gm/dl similar to 2.8±0.445 gm/dl as observed by Li et al and close to 2.596±7.48gm/dl as observed by Brohi. Prothrombin time and serum albumin are important prognostic markers of fulminant hepatic failure.

Most common complication observed in our patients was cerebral edema (44.82%) while other complications observed were renal failure (24.13%) and bleeding (20.68%). Likewise Shinde observed GI bleed in 25% and renal failure in 21% cases. However Brohi observed complications less frequently (cerebral edema in 3.8% cases, renal failure in 7.7% and PPH in 16.2%). We observed complications more frequently in our patients stressing the need of intensive care.

We observed an overall mortality of 37.93% which is much higher than other studies. Brohi observed mortality rate of 28.8% and Sahai in 19.11%. This could be because of delay in access to medical facilities.

Fetal mortality in our study was 72.4%, comparable with 77% in Brohi’s study but much higher than that observed by Sahai (42.6%).

In 17.24% patients, pregnancy was terminated on therapeutic grounds to save the life of mother. 44.82% of our patients had spontaneous expulsion of fetus. 36.36% cases observed by Sahai et al had spontaneous delivery and it was more common in those patients who survived. In remaining patients (37.93%) pregnancy continued and either the patient died or was discharged on request.

No significant difference was observed in clinical and biochemical parameters among the three groups. However it was observed that mortality rate (20%) is much lower if pregnancy was terminated as compared to (45.5%) when pregnancy was continued. Although bleeding occurred more frequently (40%) in patients who underwent termination, it was managed successfully as confirmed by low mortality in this group. However Banait et al did not find any difference in maternal mortality in patients who delivered as compared to those who did not.

To our knowledge few studies have been done to see maternal outcome in FHF and no such study has been done in our setup. Pregnant women with viral hepatitis have exaggerated immune response which triggers fulminant hepatic failure, so it should be logical to deliver the fetus as soon as possible to save the life of mother as is done in HELLP syndrome and acute fatty liver of pregnancy.

It was a limited observational study with a small sample size. Another study with larger sample size can be done to prove it further.

CONCLUSION

Jaundice with altered level of consciousness is the most common presentation. Hepatitis E is the most common cause of fulminant hepatic failure in pregnancy. Patients with FHF in pregnancy present late and maternal mortality rate is very high specially if pregnancy continues.

There is a dire need for provision of a clean and healthy environment to pregnant women as yet no vaccine is available against HEV in Pakistan. In order to reduce maternal and perinatal death rate in FHF, antenatal health services should be improved with early referrals to tertiary care hospitals. Liver transplant program in Pakistan should provide this facility in tertiary care hospitals in South Punjab. Early delivery should be attempted to save the life of mother.

Copyright© 15 Mar, 2021.
REFERENCES

1. Patra S, Kumar A, Trivedi SS, Puri M, Sarin SK. Maternal and fetal outcomes in pregnant women with acute Hepatitis E virus infection. Ann Intern Med. 2007; 147(1):28-33. doi:10.7326/0003-4819-147-1-200707030-00005.

2. Pandey CK, Karna ST, Pandey VK, Tandon M. Acute liver failure in pregnancy: Challenges and management. Indian J Anaesth. 2015; 59(3):144–49. doi: 10.4103/0019-5049.153035.

3. Li XM, Ma L, Yang YB, Shi ZJ, Zhou SS. Clinical characteristics of fulminant hepatitis in pregnancy. World J Gastroenterol. 2005; 11(29):4600-3. doi:10.3748/wjg.v11.i29.4600.

4. Paschoal FMJ, Nogueira RC, Oliveira ML, Paschoal EHA, Teixeira MJ, D’Albuquerque LAC, et al. Cerebral hemodynamic and metabolic changes in fulminant hepatic failure. Arq Neuropsiquiatr. 2017; 75(7):470-76. doi:10.1590/0004-282X201700076.

5. Shalimar, Acharya SK. Hepatitis E and acute liver failure in pregnancy. J Clin Exp Hepatol. 2013 Sep; 3(3):213-24. doi: 10.1016/j.jceh.2013.08.009.

6. Karna R, Hazam RK, Borkakoti J, Kumar A, Kar P. A 5-year single-center experience of Hepatitis E Virus Infection during pregnancy. J Clin Exp Hepatol. 2020; 10(2):135-38. doi: 10.1016/j.jceh.2019.09.003.

7. Shinde NR, Patil TB, Deshpande AS, Gulhane RV, Patil MB, Bansod YV. Clinical profile, maternal and fetal outcomes of acute hepatitis E in pregnancy. Ann Med Health Sci Res. 2014; 4(8):133-9. doi:104103/2141-9248.138033.

8. Desai A, Kansara V, Oza H, Ninama P, Paryani DJ. The prognosis of fulminant hepatic failure in pregnant women due to Hepatitis E. Euroasian J Hepato-Gastroenterol. 2013; 3(2):94-96.

9. Brohi ZP, Sadaf A, Perveren U. Etiology, clinical features and outcome of fulminant hepatic failure in pregnancy. J Pak Med Assoc. 2013; 63(9):1168-71. PMID: 24601199.

10. Khuroo MS, Kamili S. Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy. J Viral Hepat. 2003; 10(1):61-9. doi: 10.1046/j.1365-2893.2003.00398.x.

11. Sahai S, Kiran R. Acute liver failure in pregnancy: Causative and prognostic factors. Saudi J Gastroenterol. 2015; 21(1):30-34. doi:10.4103/1319-3767.151221.

12. Patra S, Kumar A, Trivedi SS, Puri M, Sarin SK. Maternal and fetal outcomes in pregnant women with acute hepatitis E virus infection. Ann Intern Med. 2007; 147(1):28-33.

13. Shuaib M, Ashraf R, Imranullah M, Nadeem M. Hepatitis-E induced fulminant hepatic failure in pregnancy and its associated mortality. JIMDC; 2015;4(3):96-98.

14. Navaneethan U, Al Mohajer M, Shata MT. Hepatitis E and pregnancy: Understanding the pathogenesis. Liver Int. 2008; 28(9):1190-99. doi: 10.1111/j-1478-3231.2008. 01840.x.

15. Beniwal M, Kumar A, Kar P, Jilani N, Sharma JB. Prevalence and severity of acute viral hepatitis and fulminant hepatitis during pregnancy: A prospective study from North India. Indian J Med Microbiol. 2003; 21(3):184-5. PMID: 17643015.

16. Gordon FD, Anastopoulos H, Khettry U, Loda M, Jenkins RL, Lewis WD, et al. Hepatitis C infection: A rare cause of fulminant hepatic failure. Am J Gastroenterol. 1995; 90(1):117-20. PMID: 7801910.

17. Younis BB, Arshad R, Khurhsid S, Masood J, Nazir F, Tahira M. Fulminant hepatic failure (FHF) due to acute hepatitis C. Pak J Med Sci. 2015; 31(4):1009-11. doi: 10.12669/pjms.314.7618.

18. Banait VS, Sandur V, Parikh F, Murugesh M, Ranika P, Ramesh VS, et al. Outcome of acute liver failure due to acute hepatitis E in pregnant women. Indian J Gastroenterol. 2007; 26(1):6-10. PMID: 17401226.

19. Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: Clinical issues and management. A Review. BMC Pregnancy Childbirth. 2009; (26)9:8. doi: 10.1186/1471-2393-9-8. PMID: 19245695; PMCID: PMC2654858.

20. Liu J, Ghaziani TT, Wolf JL. Acute fatty liver disease of pregnancy: Updates in pathogenesis, diagnosis, and management. Am J Gastroenterol. 2017; 112(6):838-46. doi: 10.1038/ajg.2017.54.
### AUTHORSHIP AND CONTRIBUTION DECLARATION

| Sr. # | Author(s) Full Name | Contribution to the paper | Author(s) Signature |
|-------|---------------------|---------------------------|---------------------|
| 1     | Zahra Nazish        | Acquisition analysis and interpretation of data, Manuscript writing. |                     |
| 2     | Muhammad Inayatullah | Conception of work, Final approval. |                     |
| 3     | Fatima Tu Zahra     | Data interpretation, Revising critically. |                     |